aDepartment of Pediatrics A, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer bDepartment of Pediatrics, Hadassah Hebrew University Medical Center, Mount Scopus, Jerusalem, Israel.
Curr Opin Rheumatol. 2016 Sep;28(5):523-9. doi: 10.1097/BOR.0000000000000315.
Familial Mediterranean fever (FMF) is the oldest and most common of the hereditary autoinflammatory diseases (AIDs). A large body of information has been accumulated over recent years on the pathophysiology, diagnosis and treatment of these diseases. The purpose of this review is to bring an up-to-date summary of the clinic manifestations, diagnostic criteria and treatment of FMF.
An overview of the pathophysiologic basis of FMF as part of the AID is discussed. Over the last year, attempts to establish new criteria for childhood FMF, new guidelines for treatment and follow-up of disease and novel treatment for FMF were made. A comparison of the different disease severity scores for research purposes suggests that a new score is needed. New evidence for antiinterleukin-1 blockade as a new treatment modality is described.
New diagnostic criteria, disease severity score, treatment and follow-up guidelines have been proposed, and need validation in the next several years.
家族性地中海热(FMF)是遗传性自身炎症性疾病(AIDs)中最古老和最常见的疾病。近年来,人们积累了大量关于这些疾病的病理生理学、诊断和治疗的信息。本文的目的是对 FMF 的临床表现、诊断标准和治疗进行最新总结。
本文讨论了 FMF 作为 AID 的病理生理基础的概述。在过去的一年中,人们尝试建立儿童 FMF 的新标准、疾病治疗和随访的新指南以及治疗 FMF 的新方法。为了研究目的,对不同疾病严重程度评分进行比较后,提示需要制定新的评分。描述了针对白细胞介素-1 阻断作为一种新的治疗方式的新证据。
新的诊断标准、疾病严重程度评分、治疗和随访指南已经提出,需要在未来几年内进行验证。